Intellipharmaceutics International Inc.
IPCIF · OTC
11/30/2022 | 11/30/2021 | 11/30/2020 | 11/30/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | $1 |
| % Growth | 0% | -95.3% | 0% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $1 | $1 |
| % Margin | 100% | -290.2% | 69.3% | 97.6% |
| R&D Expenses | $2 | $2 | $3 | $4 |
| G&A Expenses | $0 | $1 | $1 | $0 |
| SG&A Expenses | $1 | $1 | $1 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3 | $3 | $4 | $6 |
| Operating Income | -$3 | -$3 | -$4 | -$5 |
| % Margin | -4,336.8% | -4,336.8% | -297.8% | -333.8% |
| Other Income/Exp. Net | $0 | -$0 | -$1 | $1 |
| Pre-Tax Income | -$3 | -$3 | -$5 | -$3 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | -$3 | -$3 | -$5 | -$3 |
| % Margin | -4,400.6% | -4,400.6% | -367.1% | -241.9% |
| EPS | -0.087 | -0.098 | -0.22 | -0.16 |
| % Growth | 11.1% | 55.3% | -37.5% | – |
| EPS Diluted | -0.087 | -0.098 | -0.22 | -0.16 |
| Weighted Avg Shares Out | 33 | 29 | 24 | 22 |
| Weighted Avg Shares Out Dil | 33 | 29 | 24 | 22 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $1 | $0 |
| Interest Expense | $0 | $0 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $1 |
| EBITDA | -$3 | -$3 | -$4 | -$2 |
| % Margin | -4,023.3% | -4,023.3% | -279.1% | -125.8% |